What it sells
World's Earliest Test for Alzheimer's Biomarkers
Business model breakdown
Buyer: who owns the budget?
UnverifiedClinics and memory-care providers administering the screening; older adults 65+ are the tested population.
Trigger: what makes them buy now?
Alzheimer changes begin years before memory loss; FDA-approved Leqembi and Kisunla work best in early stages, so early identification matters.
Workflow: what inputs become what output?
Patient visits clinic, staff fit a VR headset, patient performs five eye-movement tasks (hold gaze, look toward, look away, respond as dots change, follow), infrared cameras record, staff check recording; results reviewed with clinician.
Distribution: how it reaches customers
Delivered through clinics/staff-administered visits; Take the test CTA; admin@saccade.health contact.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Fall 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.